Study title:
Development of a combined vaccine against equine influenza and tetanus. Experiment outside containment (clinical trial) for the study of the safety and efficacy of an intramuscular administration of recombinant canarypoxvirus expressing equine influenza v
EU record number:
B/BE/00/V15
Company / Sponsor:
Merial
Treated organism:
Horses
Indication category:
vaccination against equine influenza virus
Genetic modification:
haemagglutinin gene from equine influenza virus A2/Kentucky/94 or equine influenza virus A2/Newmarket/2/93
Method of transfer of nucleic acid of interest:
Canarypoxvirus (ALVAC clone)
Route of administration:
Intramuscular
Locations in Belgium:
Gentbrugge and Bornem
Nr of subjects:
50
Foreseen duration:
12 months
Type of procedure:
Deliberate release only
Information for the public
Information related to the decision procedure
-
5 January: The Regional Competent Minister issues a positive advice with conditions
-
14 March: The Federal Public Service Health, Food chain safety and Environment gives a final decision (positive with conditions) for this trial.
-
18 December 2000: The Biosafety Advisory Council a.i. issues an advice (positive with conditions) for this trial (the advice is written in French)